Abstract
Ten Turner syndrome girls whose mean age was 10.9 +/- 2.7 years were treated with recombinant human growth hormone (rhGH), dose 0.6 U/kg/week. Five of them had classical 45, XO karyotype. The mean height velocity increased from 2.8 +/- 1.3 cm/year before treatment to 6.1 +/- 2.06 cm/year after treatment for a period of 1.4 years. The response of treatment correlated well with pretreatment height velocity (<3 cm/year) but not with karyotype. However, the response has been decreasing and an increased dose after the first year of treatment is recommended.
MeSH terms
-
Adolescent
-
Body Height / drug effects
-
Bone Development
-
Child
-
Clonidine / therapeutic use
-
Estradiol / blood
-
Female
-
Follicle Stimulating Hormone / blood
-
Follow-Up Studies
-
Glycated Hemoglobin / analysis
-
Gonadotropin-Releasing Hormone
-
Growth Hormone / blood
-
Growth Hormone / therapeutic use*
-
Growth*
-
Humans
-
Karyotyping
-
Luteinizing Hormone / blood
-
Recombinant Proteins / therapeutic use
-
Thyroid Function Tests
-
Time Factors
-
Turner Syndrome / drug therapy*
-
Turner Syndrome / genetics
-
Turner Syndrome / physiopathology*
Substances
-
Glycated Hemoglobin A
-
Recombinant Proteins
-
Gonadotropin-Releasing Hormone
-
Estradiol
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
Growth Hormone
-
Clonidine